A blood marker that predicts trouble in later life still needs to earn its place in research on exceptional survivors. Fred Hutch Cancer Center announced on October 1 that epidemiologist Alexander Reiner has received a five-year, $3.5 million National Institute on Aging award to investigate clonal hematopoiesis of indeterminate potential, or CHIP, in older women. The project creates an opportunity to examine a question that existing studies have answered differently: what does carrying a blood-cell mutation mean after age 80?
CHIP involves the expansion of blood cells descended from a cell with an acquired mutation, without other defining blood abnormalities. The new work draws on the Women’s Health Initiative. Fred Hutch describes existing measurements at two time points in 7,000 women, with additional baseline measurements planned. The announcement describes research to be done, not new evidence that CHIP shortens life or that measuring it improves health.
Analysis: make the disagreement useful
TENS Magazine’s assessment is that the project’s value will depend on how well it separates three questions: whether a clone is detectable, whether its particular features predict an outcome, and whether that information adds something useful beyond what researchers already know. Treating those questions as interchangeable would turn a sophisticated blood measurement into an overly simple label.
Consider two peer-reviewed studies published in 2021. A Blood Advances analysis of 621 LifeLines participants aged at least 80 used sensitive sequencing across 27 genes, detecting variants at a frequency of 1% or more. It found clonal hematopoiesis in 62% of participants. Overall detection was not associated with higher mortality: the hazard ratio was 0.91, with a 95% confidence interval from 0.70 to 1.18. That interval does not establish protection.
The same study found that the genetic pattern mattered. Participants with mutations beyond DNMT3A and TET2 had higher mortality than those whose mutations were confined to those two genes. A separate Blood study screened 1,794 people aged at least 80 and found mutations in roughly one-third; mutations were associated with reduced survival. It also identified different implications for particular mutation patterns and showed that combining genetic information with red-cell measurements improved prediction of myeloid neoplasms.
Our reading is that the apparent disagreement should shape the new investigation, rather than be edited out of its background. Neither a reassuring overall average nor an adverse association can stand in for every mutation pattern. These were different populations and analyses. Their percentages are not interchangeable prevalence estimates, and they do not demonstrate that risk changed between studies.
The definition belongs beside the result
The first reporting priority should be a clear account of what counts as a detected clone. A sensitive search can identify smaller populations of mutated cells that another method misses. Consequently, a broad clonal-hematopoiesis result should not automatically be read as equivalent to a CHIP result under another definition. We would want gene coverage, detection thresholds and clone-size groupings presented alongside any headline association.
That is an editorial standard for interpretation, not a finding that measurement alone explains the earlier disagreement. Participant health, selection into a cohort, follow-up and outcome definitions may also matter. A study of people who have already reached advanced age describes survivors; it cannot automatically reconstruct the experiences of everyone who began aging decades earlier. Larger numbers improve the opportunity to investigate those distinctions, but do not erase them.
The second priority is to keep outcomes separate. Living longer, remaining mobile and avoiding several chronic diseases are related ambitions, but they are not the same measurement. Fred Hutch says the project will investigate exceptional longevity, mobility impairment and multimorbidity. A result for one should be reported as such, even if another is unchanged or uncertain. That separation would make an eventual mixed result scientifically informative.
Prediction has its own test
Repeated blood measurements offer a way to ask whether changes in a clone carry information beyond a single sample. Our proposed test is incremental value: compare a model using established participant characteristics with one that also uses the clonal information, then examine how accurately each predicts the stated outcome in people outside the development sample. Finding an association and improving a prediction are distinct achievements.
Replication also needs a defined purpose. Fred Hutch plans to extend key findings using UK Biobank and the Jackson Heart Study, including men. Agreement across cohorts would strengthen confidence, while differences could reveal limits to generalization. Either result should be judged against differences in participants and measurement, rather than reduced to a single success-or-failure verdict.
The evidence discussed here is human observational research plus a newly announced research program. It does not establish that removing clones, ordering a screening test or changing treatment extends lifespan or healthspan. The immediate advance is a chance to resolve which blood-cell changes remain informative at exceptional ages. For longevity science, a well-defined answer to that narrower question would be more useful than treating every detectable mutation as a universal measure of aging.
Sources: Fred Hutch Cancer Center; Blood Advances; Blood.
TENS Magazine conceptual illustration
